Network News

EMBL and ELLIS deepen relationship to drive artificial intelligence (AI) in European life science research, training, and technology A new collaborative agreement aims to help position Europe at the forefront of AI-driven advancements in life sciences research. The European Molecular Biology Laboratory (EMBL) and the European Laboratory for Learning and Intelligent Systems (ELLIS) have agreed […]

Study identifies a novel mechanism driving osteosarcoma and provides insights to help predict patient outcomes Summary Osteosarcoma is a type of aggressive bone cancer that most commonly affects children and young adults between the ages of 10 and 20, during times of rapid bone growth. Although rare, it has a significant impact on young people […]

If the development of blood vessels in the placenta is impaired, fetal growth retardation may result. Scientists from the German Cancer Research Center (DKFZ) and the Mannheim Medical Faculty of Heidelberg University discovered that the correct development of functioning blood vessels in the mouse placenta is controlled epigenetically: One of the enzymes that modify gene […]

Alcedis is a globally operating, leading full-service CRO with over 30 years of experience in clinical research. As a member of the Huma Group, they combine deep expertise with innovative AI-driven technologies to conduct clinical trials efficiently and accurately – from Phase I to market authorization, medical device projects, and real-world evidence. Their in-house competence […]

The curATime cluster is one of 14 pioneering “Clusters4Future” initiatives funded by the German Federal Ministry of Education and Research (BMBF). Its mission is to promote personalized approaches to combat atherothrombosis-related diseases and to establish the Rhine-Main-Palatinate region as an international driver of innovation. For the planned second implementation phase, the cluster is seeking new […]

Tumor cells circulating in the blood are the “germ cells” of breast cancer metastases. They are very rare and could not be propagated in the culture dish until now, which made research into therapy resistance difficult. A team from the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute HI-STEM* and the NCT Heidelberg** […]

Heidelberg, Germany, 19.12.2024 – RHEACELL today received approval from the European Medicines Agency (EMA) for its blinded, multi-centric Phase-3 trial (NCT06489028) evaluating allo-APZ2-CVU in patients with chronic venous ulcers (CVU). The pivotal trial will be conducted at more than 100 sites and is expected to enroll 250 patients, starting enrollment in Europe in Q1 2025. […]

EMBL scientists discover that an FDA-approved, over-the-counter cough syrup ingredient has potential to treat fibrotic lung disease. Summary A common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions.  Scientists from EMBL Heidelberg were part of a […]

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December […]